Sucampo Pharmaceuticals (SCMP) PT Set at $23.00 by Maxim Group
Sucampo Pharmaceuticals (NASDAQ:SCMP) has been given a $23.00 price target by Maxim Group in a research note issued to investors on Thursday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s price objective suggests a potential upside of 47.44% from the stock’s current price.
The analysts wrote, “Sucampo’s stock has risen sharply in the past few weeks (from ~$10 to $16+) on no new fundamental news. However, a Bloomberg story has been circulating that the company may be entertaining suitors. We have no specific knowledge to confirm this, but do see an undervalued company that is generating free cash flow and has a strong (orphan) pipeline. Our last note (from 11/21) reviewed the R&D Day which focused on two key pipeline products, VTS-270 (Neeman Pick Disease) and CPP-1X/sulindac (Familial Adenomatous Polyposis ).””
A number of other equities research analysts also recently issued reports on SCMP. Leerink Swann started coverage on shares of Sucampo Pharmaceuticals in a research report on Monday, August 21st. They set an “outperform” rating and a $15.00 price objective for the company. Mizuho downgraded shares of Sucampo Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price objective for the company from $14.00 to $12.00 in a research report on Tuesday, October 3rd. Zacks Investment Research raised shares of Sucampo Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 3rd. UBS cut their price objective on shares of Sucampo Pharmaceuticals from $19.00 to $15.00 and set a “buy” rating for the company in a research report on Thursday, October 12th. Finally, B. Riley began coverage on shares of Sucampo Pharmaceuticals in a research report on Tuesday, November 14th. They set a “buy” rating and a $14.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. Sucampo Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $16.60.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.25 by $0.02. Sucampo Pharmaceuticals had a negative net margin of 60.24% and a positive return on equity of 74.58%. The firm had revenue of $61.27 million during the quarter, compared to the consensus estimate of $58.05 million. During the same quarter in the previous year, the firm posted $0.30 EPS. The company’s revenue for the quarter was up 5.9% compared to the same quarter last year. sell-side analysts expect that Sucampo Pharmaceuticals will post 1.12 earnings per share for the current fiscal year.
In related news, major shareholder Sachiko Kuno sold 1,000,000 shares of the company’s stock in a transaction on Monday, September 11th. The shares were sold at an average price of $12.00, for a total value of $12,000,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 4.13% of the company’s stock.
A number of institutional investors have recently modified their holdings of the stock. GSA Capital Partners LLP boosted its holdings in Sucampo Pharmaceuticals by 636.4% in the 3rd quarter. GSA Capital Partners LLP now owns 112,170 shares of the biopharmaceutical company’s stock worth $1,324,000 after buying an additional 96,937 shares during the period. Dana Investment Advisors Inc. boosted its holdings in Sucampo Pharmaceuticals by 7.5% in the 3rd quarter. Dana Investment Advisors Inc. now owns 201,538 shares of the biopharmaceutical company’s stock worth $2,378,000 after buying an additional 14,089 shares during the period. Argent Capital Management LLC bought a new position in Sucampo Pharmaceuticals in the 3rd quarter worth $1,067,000. Point72 Asset Management L.P. bought a new position in Sucampo Pharmaceuticals in the 3rd quarter worth $21,989,000. Finally, Royce & Associates LP lifted its stake in Sucampo Pharmaceuticals by 9.7% in the 3rd quarter. Royce & Associates LP now owns 1,171,731 shares of the biopharmaceutical company’s stock worth $13,826,000 after purchasing an additional 103,808 shares in the last quarter. 65.31% of the stock is owned by institutional investors.
TRADEMARK VIOLATION NOTICE: “Sucampo Pharmaceuticals (SCMP) PT Set at $23.00 by Maxim Group” was published by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this story can be read at https://www.americanbankingnews.com/2017/12/07/sucampo-pharmaceuticals-scmp-buy-rating-reaffirmed-at-maxim-group.html.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.